Edition:
United Kingdom

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

563.00GBp
20 Sep 2018
Change (% chg)

11.00 (+1.99%)
Prev Close
552.00
Open
552.00
Day's High
565.00
Day's Low
551.00
Volume
1,087,278
Avg. Vol
938,027
52-wk High
784.00
52-wk Low
467.40

Latest Key Developments (Source: Significant Developments)

BTG Plc Acquires Novate Medical Ltd
Friday, 7 Sep 2018 

Sept 7 (Reuters) - BTG PLC ::BTG PLC ACQUIRES NOVATE MEDICAL LTD.PAID $20M IN CASH TO ACQUIRE NOVATE AND MAY BE REQUIRED TO PAY ADDITIONAL CASH CONSIDERATIONS UP TO $130M.TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EPS FROM SECOND FULL YEAR OF OWNERSHIP.  Full Article

BTG Gets Not-Approvable Letter From U.S. FDA For ELEVAIR
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - BTG PLC ::BTG RECEIVES NOT-APPROVABLE LETTER FROM US FDA FOR ELEVAIR.PNEUMRX HAS RECEIVED CONFIRMATION FROM US FOOD AND DRUG ADMINISTRATION (FDA) THAT PREMARKET APPROVAL (PMA) APPLICATION FOR ITS ELEVAIR ENDOBRONCHIAL COIL SYSTEM FOR TREATMENT OF PEOPLE WITH SEVERE EMPHYSEMA IS NOT APPROVABLE.THIS FOLLOWS FDA ADVISORY PANEL'S RECOMMENDATION IN JUNE 2018 NOT TO APPROVE ELEVAIR.BTG IS REVIEWING OPTIONS AND WILL PROVIDE AN UPDATE IN DUE COURSE.PNEUMRX CONFIRMATION FROM FDA THAT PREMARKET APPROVAL APPLICATION FOR ELEVAIR ENDOBRONCHIAL COIL SYSTEM IS NOT APPROVABLE.  Full Article

BTG PLC Reiterates Guidance For Full Year
Wednesday, 18 Jul 2018 

July 18 (Reuters) - BTG PLC ::TRADING SINCE 1 APRIL 2018 IS IN LINE WITH EXPECTATIONS AND BOARD REITERATES ITS GUIDANCE FOR FULL YEAR.  Full Article

BTG full-year operating profit up 18 pct
Tuesday, 15 May 2018 

May 15 (Reuters) - BTG PLC ::FY REVENUE 620.5 MILLION STG, UP 9 PERCENT.ADJUSTED OPERATING PROFIT 152.7 MILLION STG, UP 18 PERCENT.ADJUSTED BASIC EPS 1 32.9P UP 42 PERCENT.  Full Article

BTG says 2017/18 results hit by 150 million pound impairment charge
Thursday, 5 Apr 2018 

April 5 (Reuters) - BTG PLC ::BTG HAS DELIVERED A GOOD FINANCIAL PERFORMANCE FOR YEAR, WITH REVENUE IN LINE WITH EXPECTATIONS.VERY GOOD GROWTH IN INTERVENTIONAL MEDICINE PRODUCT SALES REFLECTS MID-TEENS CER 1 GROWTH IN ONCOLOGY AND VASCULAR PORTFOLIOS, WHICH TOGETHER REPRESENT >90% OF REVENUE IN THIS BUSINES.LOWER SALES OF PNEUMRX ® COILS REFLECT THAT MARKET DEVELOPMENT, INCLUDING SECURING APPROPRIATE LEVELS OF REIMBURSEMENT, IS TAKING LONGER THAN EXPECTED.WE DO NOT EXPECT MATERIAL REVENUES FROM THIS PRODUCT OVER NEXT TWO YEARS.WE HAVE THEREFORE REASSESSED FAIR VALUE OF THIS ASSET, AND OUR FINANCIAL RESULTS FOR 2017/18 WILL INCLUDE AN IMPAIRMENT CHARGE OF APPROXIMATELY £150M.IN ADDITION, OUR 2018/19 RESULTS WILL INCLUDE A ONE-OFF RESTRUCTURING CHARGE OF UP TO £10M.  Full Article

BTG says Zytiga royalties guidance unchanged after patent setback
Wednesday, 17 Jan 2018 

Jan 18 (Reuters) - BTG ::SPOKESMAN SAYS PREVIOUS GUIDANCE ON ZYTIGA ROYALTIES IS UNCHANGED, DESPITE U.S. ADMINISTRATIVE COURT DECISION TO INVALIDATE PATENT.BELIEVES EARLIEST LIKELY U.S. GENERIC ENTRY WOULD BE OCTOBER 2018, WHICH IS ALREADY REFLECTED IN THE CONSENSUS OF ANALYSTS.  Full Article

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

BTG H1 ‍adjusted operating profit of 99.1 mln stg vs 78.8 mln stg
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Btg Plc :H1 REVENUE 341.3 MILLION STG.H1 ‍ADJUSTED OPERATING PROFIT OF 99.1 MILLION STG VERSUS 78.8 MILLION STG YEAR AGO​.BTG PLC - ‍FURTHER GROWTH IS EXPECTED IN H2 IN INTERVENTIONAL MEDICINE PRODUCT SALES ​.BTG PLC - ‍PHARMACEUTICALS REVENUES IN H2 WILL REFLECT H1-WEIGHTED SEASONALITY OF CROFAB AND FEWER ANTICIPATED EXPIRY ORDERS FOR DIGIFAB COMPARED WITH H2 2016/17​.‍GROUP'S OVERALL OUTLOOK FOR FULL YEAR TO 31 MARCH 2018 REMAINS UNCHANGED​.  Full Article

BTG's Biocompatibles to settle LC Bead probe for $36 mln
Thursday, 6 Oct 2016 

BTG Plc : Settlement of U.S. investigation into LC Bead . Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead . Says Biocompatibles has agreed to settle all allegations and consequently to pay a total penalty of $36 mln .Investigation focused on period pre-dating BTG's acquisition of Biocompatibles in January 2011.  Full Article

Deals of the day-Mergers and acquisitions

Sept 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: